Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer

References

• Felsenfeld G, Groudine M. Controlling the double helix. Nature 2003; 421:448 - 453; PMID: 12540921
   PubMed Web of Science ®Google Scholar
• Becker PB, Hörz W. ATP-dependent nucleosome remodeling. Annu Rev Biochem 2002; 71:247 - 273; PMID: 12045097
   PubMed Web of Science ®Google Scholar
• Holbert MA, Marmorstein R. Structure and activity of enzymes that remove histone modifications. Curr Opin Struct Biol 2005; 15:673 - 680; PMID: 16263263
   PubMed Web of Science ®Google Scholar
• Turner BM. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol 2005; 12:110 - 112; PMID: 15702071
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38 - 51; PMID: 16397526
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani R, Marks P. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541 - 5552; PMID: 17694093
   PubMed Web of Science ®Google Scholar
• Zhou Q, Melkoumian Z, Lucktong A, Moniwa M, Davie J, Strobl J. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 2000; 275:35256 - 35263; PMID: 10938272
   PubMed Web of Science ®Google Scholar
• Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15:3947 - 3957; PMID: 19509170
   PubMed Web of Science ®Google Scholar
• Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 2010; 1:596 - 605; PMID: 21317455
   PubMed Web of Science ®Google Scholar
• Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche T, et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007; 99:1107 - 1119; PMID: 17623797
   PubMed Web of Science ®Google Scholar
• Kim MS, Blake M, Baek J, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63:7291 - 7300; PMID: 14612526
   PubMed Web of Science ®Google Scholar
• Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, et al. Histone deacetylase inhibitor LAQ824 downregulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B. Mol Cancer Ther 2003; 2:971 - 998; PMID: 14578462
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jung M, Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004; 161:667 - 674; PMID: 15161353
   PubMed Web of Science ®Google Scholar
• Camphausen K, Tofilon P. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007; 25:4051 - 4056; PMID: 17827453
   PubMed Web of Science ®Google Scholar
• Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007; 74:659 - 671; PMID: 17498667
   PubMed Web of Science ®Google Scholar
• Puglisi M, Dolly S, Faria A, Myerson J, Popat S, O'Brien M. Treatment options for small cell lung cancer—do we have more choice?. Br J Cancer 2010; 102:629 - 638; PMID: 20104223
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb J, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14:804 - 810; PMID: 18245542
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010; 148:256 - 267; PMID: 19874311
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner B. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459 - 5468; PMID: 19826124
   PubMed Web of Science ®Google Scholar
• Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, et al. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle 2010; 9:3945 - 3955; PMID: 20935470
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara J, Maggio S, Coe S, Atadja P, Dent P, et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 2008; 7:3285 - 3297; PMID: 18852132
   PubMed Web of Science ®Google Scholar
• Kurz EU, Wilson S, Leader K, Sampey B, Allan W, Yalowich J, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001; 1:121 - 131; PMID: 12467229
   PubMed Web of Science ®Google Scholar
• Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle 2007; 6:371 - 376; PMID: 17297310
   PubMed Web of Science ®Google Scholar
• Schonn I, Hennesen J, Dartsch D. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis 2010; 15:162 - 172; PMID: 20041303
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson N, Poirier G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53:3976 - 3985; PMID: 8358726
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9:338 - 350; PMID: 19377506
   PubMed Web of Science ®Google Scholar
• Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996; 18:505 - 513; PMID: 8787538
   PubMed Web of Science ®Google Scholar
• Bonner WM, Redon C, Dickey J, Nakamura A, Sedelnikova O, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008; 8:957 - 967; PMID: 19005492
   PubMed Web of Science ®Google Scholar
• Sokolov MV, Dickey JS, Bonner WM, Sedelnikova OA. gammaH2AX in bystander cells: not just a radiation-triggered event, a cellular response to stress mediated by intercellular communication. Cell Cycle 2007; 6:2210 - 2212; PMID: 17881892
   PubMed Web of Science ®Google Scholar
• Nakamura AJ, Rao VA, Pommier Y, Bonner WM. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle 2010; 9:389 - 397; PMID: 20046100
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440 - 446; PMID: 20068163
   PubMed Web of Science ®Google Scholar
• Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006; 28:1233 - 1241; PMID: 16596240
   PubMed Web of Science ®Google Scholar
• Hajji N, Wallenborg K, Vlachos P, Nyman U, Hermanson O, Joseph B. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene 2008; 27:3134 - 3144; PMID: 18071312
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Bates S. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009; 15:3918 - 3926; PMID: 19509169
   PubMed Web of Science ®Google Scholar
• Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17:1144 - 1151; PMID: 20802485
   PubMed Web of Science ®Google Scholar
• Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009; 8:3075 - 3087; PMID: 19887547
   PubMed Web of Science ®Google Scholar
• Yu C, Friday B, Lai J, McCollum A, Atadja P, Roberts L, et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 2007; 13:1140 - 1148; PMID: 17317822
   PubMed Web of Science ®Google Scholar
• Munshi A, Tanaka T, Hobbs M, Tucker S, Richon V, Meyn R. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gammaH2AX foci. Mol Cancer Ther 2006; 5:1967 - 1974; PMID: 16928817
   PubMed Web of Science ®Google Scholar
• Robles AI, Wright M, Gandhi B, Feis S, Hanigan C, Wiestner A, et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res 2006; 12:6547 - 6556; PMID: 17085670
   PubMed Web of Science ®Google Scholar
• Koll TT, Feis S, Wright M, Teniola M, Richardson M, Robles A, et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 2008; 7:1985 - 1992; PMID: 18645008
   PubMed Web of Science ®Google Scholar
• Bevins RL, Zimmer S. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 2005; 65:6957 - 6966; PMID: 16061681
   PubMed Web of Science ®Google Scholar
• de Ruijter AJ, Leen R, Hoebink J, Caron H, van Kuilenburg A. Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor and gemcitabine to neuroblastoma cells. Cancer Lett 2006; 233:240 - 246; PMID: 15907366
   PubMed Web of Science ®Google Scholar
• Conti C, Leo E, Eichler G, Sordet O, Martin M, Fan A, et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins and induces DNA damage. Cancer Res 2010; 70:4470 - 4480; PMID: 20460513
   PubMed Web of Science ®Google Scholar
• Harr MW, Willey J. The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines. Int J Oncol 2007; 30:1553 - 1560; PMID: 17487378
   PubMed Web of Science ®Google Scholar
• Kaye FJ. Molecular biology of lung cancer. Lung Cancer 2001; 34:35 - 41; PMID: 11720739
   PubMed Web of Science ®Google Scholar
• Rabik CA, Fishel M, Holleran J, Kasza K, Kelley M, Egorin M, et al. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther 2008; 327:442 - 452; PMID: 18664592
   PubMed Web of Science ®Google Scholar
• McGahan MC, Tyczkowska K. The determination of platinum in biological materials by electrothermal atomic absorption spectroscopy. Spectrochimia Acta 1987; 42:665; PMID: 509738
   PubMed Web of Science ®Google Scholar
• Zhang YW, Jones T, Martin S, Caplen N, Pommier Y. Implication of checkpoint kinase-dependent upregulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem 2009; 284:18085 - 18095; PMID: 19416980
   PubMed Web of Science ®Google Scholar